Allovectin-7 therapy in metastatic melanoma

Expert Opinion on Biological Therapy

Volumn 8, Issue 6, 2008, Pages 839-844

  Bedikian, Agop Y ^a   Del Vecchio, Michele ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Allovectin 7; DNA vaccination; Immunotherapy; Melanoma

Indexed keywords

ALLOVECTIN 7; BETA 2 MICROGLOBULIN; DACARBAZINE; DNA VACCINE; HLA B7 ANTIGEN; PLASMID DNA; TEMOZOLOMIDE;

ADD ON THERAPY; ANTIGEN SPECIFICITY; ARTHRALGIA; ASTHENIA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MIGRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA IMMUNIZATION; DNA TRANSFECTION; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ECCHYMOSIS; EXPRESSION VECTOR; FATIGUE; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE PAIN; LOW DRUG DOSE; MELANOMA; METASTASIS; MYALGIA; NONHUMAN; PARESTHESIA; PNEUMOTHORAX; REVIEW; RIGOR; SINGLE DRUG DOSE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VISCERAL METASTASIS;

ANIMALS; BETA 2-MICROGLOBULIN; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DNA, RECOMBINANT; DRUG SCREENING ASSAYS, ANTITUMOR; GENETIC VECTORS; HLA-B7 ANTIGEN; HUMANS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRALESIONAL; LIPIDS; LUNG NEOPLASMS; MACACA FASCICULARIS; MELANOMA; MICE; PHOSPHATIDYLETHANOLAMINES; QUATERNARY AMMONIUM COMPOUNDS; SKIN NEOPLASMS; TUMOR ESCAPE; VACCINES, DNA;

EID: 45549108291     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.6.839     Document Type: Review

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 20 07;57:43-66
2. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In: De Vita VT, Hellman S, Rosenberg SA, editors, Cancer: principles and practice of oncology. 7th edition. Philadelphia: Lippincott Williams Wilkins; 2001. p. 2012-69
3. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36
4. Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002;29:427-45
5. Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo 1998;12:571-8
6. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst 2001;93:1047-8
7. Bulkley GB, Cohen MH, Banks PM, et al. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile. Cancer 1975;36:485-94
8. Tuthill RJ, Unger JM, Liu PY, et al. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 2002;118:504-11
9. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-39
10. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18
11. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30
12. Restifo NP, Wunderlich JR. Cancer immunology. In: De Vita VT, Hellman S, Rosenberg SA, editors, Cancer: principles and practice of oncology. 7th edition. Philadelphia: Lippincott Williams Wilkins; 2005. p. 139-61
13. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone J. MHC antigens in human melanomas. Semin Cancer Biol 1991;2:35-45
14. Natali PG, Nicotra MR, Bigotti A, et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 1989;86:6719-23
15. Marincola F, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37
16. van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988;48:1019-25
17. Lew D, Parker SE, Latimer T, et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995;6:553-64
18. Plautz G, Yang Z, Wu B, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645-9
19. Nabel GJ, Nabel EG, Yang Z-Y, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11
20. Parker SE, Vahlsing HL, Serfilippi LM, et al. Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther 1995;6:575-90
21. White SA, Conry RM. Cancer vaccines: clinical applications. DNA vaccines. In: Rosenberg SA, editor, Principles and practice of the biologic therapy of cancer. 3rd edition. Philadelphia: Lippincott Williams Wilkins; 2000. p. 674-86
22. Donnelly JJ, Ulmer JB, Liu MA. Protective efficacy of intramuscular immunization with naked DNA. Ann NY Acad Sci 1995;772:40-6
23. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15:341-9
24. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibilty complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93
25. Silver HKB, Klassa RJ, Bally JB, et al. Phase I gene therapy of HLA-B7 transduction by direct injection in malignant melanoma. Proceedings of AACR 37:#2337,1996
26. Hersh EM, Figlin R, Gutheil J, et al. Intratumoral gene transfer therapy of cancer [abstract 47]. Mol Ther 2001;3(5 Suppl):S19
27. Lewis KD, Humes TN, Gonzalez R. Current status and future prospects of gene therapy: Focus on Allovectin-7 in the treatment of metastatic melanoma. Am J Cancer 2005;4:137-44
28. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of Allovectin-7, an HLA-B7/(32-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7:2285-91
29. Gonzalez RA, Hutchins LB, Nemunaitis JC, et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16(6):521-6
30. Bedikian AY, Gonzalez R, Richards J, et al. A phase II study of high-dose allovectin-7 in patients with advanced metastatic melanoma [Abstract] 2897. Proc Am Soc Clin Oncol 2003;22:720
31. Bedikian AY, Gonzalez R, Richards J, et al. E. A phase II study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. (accepted, Melanoma Research)
32. Richards J, Thompson J, Atkins MB, et al. A controlled, randomized Phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma [Abstract 1380]. Proc Am Soc Clin Oncol 2002;21